Home » BPSA Releases Extractables Guide
BPSA Releases Extractables Guide
The Bio-Process Systems Alliance (BPSA), the trade association of the single-use bio-processing industry, has released its 2010 technical guide: Recommendations for Testing and Evaluation of Extractables from Single-Use Process Equipment. The guide is available for order at www.bpsalliance.org.
The 22-page color guide is intended as a “best practices” document, to help suppliers and users of disposable single-use components and systems develop appropriate fluid-specific extractables data that may have applicability in risk-based decisions in bio-process component selections, process validation and regulatory filings.
Extractables evaluation in bio-processing is needed to assess the potential impact of process equipment migrants on process intermediates or finished drug product. The guide includes charts, graphs and decision trees to help users and suppliers initiate and document extractables evaluations that align with FDA Current Good Manufacturing Practice (cGMP) for Finished Pharmaceuticals, and is inclusive of key references and definitions.
The new 2010 Guide is a compendium of recommendations that builds upon the original BPSA Extractables Guide, parts 1 and 2, published in 2007-8, which is available for complimentary download on the BPSA website www.bpsalliance.org.
The latest BPSA Extractable Guides was developed by company experts within the BPSA organization, with specialized knowledge of extractables processes and program testing and evaluation. The document is the result of an 18-month commitment by BPSA volunteers to educate and inform end-users and suppliers of the rigorous requirements and hurdles in undertaking the development of appropriate, documentable extractables and potential leachables data, and to help users and suppliers minimize duplicative testing.
For further information, e-mail Kevin Ott, BPSA Executive Director at email@example.com, or go to www.bpsalliance.org.
Merck Stops Development of Parkinsonís DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesnít work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »